Report LibraryAll Reports
Datamonitor Healthcare I&I Disease Analysis: Rheumatoid Arthritis (RA)
January 08, 2020The rheumatoid arthritis (RA) market will experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars and encourage uptake.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Rheumatoid Arthritis (RA)|